Calluna Pharma AS, a clinical-stage biotechnology company developing first-in-class antibodies for inflammatory and fibrotic diseases, has announced initial patients have been dosed in the Phase 2 AURORA trial of the first-in-class monoclonal antibody for idiopathic pulmonary fibrosis (IPF).

The monoclonal antibody, named CAL101, targets S100A4, a damage-associated molecular pattern (DAMP) protein linked to severe and potentially life-threatening fibrotic conditions.

“S100A4 is a central mediator of both inflammation and fibrosis and, importantly, the communications between immune and stromal cells (such as fibroblasts),” Jonas Hallén, M.D. , chief medical officer of Calluna Pharma, told Managed Healthcare Executive . “It is released from stressed or injured cells, acting as an upstr

See Full Page